Evolent Announces First Quarter 2024 Results
Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%. Adjusted EBITDA of $54.1 million resulting in an Adjusted...
Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%. Adjusted EBITDA of $54.1 million resulting in an Adjusted...
